Experience

ZelosDx

• United States
• Biotechnology Research
• 1 - 100 Employee

• Board of Directors

  • May 2013 - Present

  ZelosDx is a neurodiagnostic company that develops novel blood testing products termed WINDOW INTO THE BRAIN, a patented technology that offers the potential for a real-time view of disease activity. The ZelosDx proprietary biomarker technology should be equally useful to pharmaceutical companies as tools for drug discovery and by researchers conducting studies in brain disease. ZelosDx is a neurodiagnostic company that develops novel blood testing products termed WINDOW INTO THE BRAIN, a patented technology that offers the potential for a real-time view of disease activity. The ZelosDx proprietary biomarker technology should be equally useful to pharmaceutical companies as tools for drug discovery and by researchers conducting studies in brain disease.



Susavion Biosciences,

• Biotechnology

• Consultant

  • 2012 - Present

  Susavion Biosciences is a development stage private biotechnology company with a platform of novel peptidic drugs that bind lectin-like receptors and promote activity of the immune system. A lead compound in development for the treatment of cancer, has been shown to stimulate the maturation and activation of dendritic and NK cells. Susavion Biosciences is a development stage private biotechnology company with a platform of novel peptidic drugs that bind lectin-like receptors and promote activity of the immune system. A lead compound in development for the treatment of cancer, has been shown to stimulate the maturation and activation of dendritic and NK cells.



Arizona Tech Investors

• United States
• Capital Markets
• 1 - 100 Employee

• Board Member

  • 2011 - Present

  The Arizona Tech Investors (ATI) is an active group of over 100 men and women who invest in high-potential early stage technology companies. All accredited investors, we seek out promising companies located in Arizona and in the surrounding states of the Southwest. The Arizona Tech Investors (ATI) is an active group of over 100 men and women who invest in high-potential early stage technology companies. All accredited investors, we seek out promising companies located in Arizona and in the surrounding states of the Southwest.



MCCALEB ASSOCIATES

• United States
• Real Estate
• 1 - 100 Employee

• President

  • 2007 - Present

  President of firm providing biotechnology companies with management consulting services. My consulting practice was driven by my ability to provide start up companies with insights in the creation of their strategies for the commercialization of new products and technologies. I served as senior commercial advisor for a number of major biotechnology companies during their formative stages, including Gilead Sciences, Cephalon, and CV Therapeutics. I assisted in developing and implementing commercial programs, recruiting management teams, executing partnerships and raising capital. In addition to my work with major biotech companies, I have also been involved in early stage start ups including Prothena, Coulter Pharmaceuticals, Maret Pharmaceuticals , OmniScience and XTANT. My work with these earlier stage companies often involved serving as advisor to the Board of Directors for commercial and business planning. In addition, I often contributed to successful partnering, fundraising and/or merger. With Coulter Pharmaceuticals, the fundraising led to an IPO and a listing on NASDAQ. Show less


St. Joseph Foundation
• United States
• Hospitals and Health Care
• Board of Directors

  • 2010 - Jun 2020

Venture Catalyst at ASU
• United States
• Professional Training and Coaching
• Mentor

  • 2012 - 2020

Sonoran Biosciences
• Biotechnology Research
• Board Advisor

  • 2012 - 2016

Thunderbird Angel Network
• Venture Capital and Private Equity Principals
• Member

  • 2012 - 2015

Arizona BioIndustry Association (AZBio)
• Biotechnology
• 1 - 100 Employee
• Board of Directors

  • 2010 - 2011

CV Therapeutics
• Biotechnology Research
• 100 - 200 Employee
• SVP Commercial Operations

  • 1999 - 2007

McCaleb Associates
• United States
• Real Estate
• 1 - 100 Employee
• President

  • 1994 - 1999

Amgen
• United States
• Biotechnology Research
• 700 & Above Employee
• Director Marketing

  • 1988 - 1994

Forest Laboratories
• Austria
• Medical Practices
• Marketing Manager

  • 1986 - 1988


Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Product Management

  • 1982 - 1986

• Sales Representative

  • 1981 - 1982